Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Meniere's Disease Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Deep Phenotyping of Hearing Instability Disorders: Cohort Establishment, Biomarker Identification, Development of Novel Phenotyping Measures, and Discovery of Therapeutic Targets

NCT04806282
View directory record Official record
Conditions
Meniere's Disease, Enlarged Vestibular Aqueduct Syndrome, Autoimmune Inner Ear Disease
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 4:00 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease

NCT03664674
View directory record Official record
Conditions
Meniere Disease
Interventions
OTO-104, Placebo
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
17
States / cities
Fresno, California • Aurora, Colorado • Colorado Springs, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Jul 22, 2026, 4:00 PM EDT
Terminated Phase 3 Interventional Results available

A 6-Month Extension Study of OTO-104 in Meniere's Disease

NCT02706730
View directory record Official record
Conditions
Meniere's Disease
Interventions
OTO-104
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Jul 22, 2026, 4:00 PM EDT
Completed Phase 2 Interventional

OTO-104 for the Treatment of Meniere's Disease

NCT01412177
View directory record Official record
Conditions
Meniere's Disease
Interventions
OTO-104, Placebo
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
San Diego, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Jul 22, 2026, 4:00 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes

NCT04218123
View directory record Official record
Conditions
Meniere Disease
Interventions
Venlafaxine, Placebo oral tablet
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Jul 22, 2026, 4:00 PM EDT
Completed Phase 3 Interventional Results available

Study of OTO-104 in Subjects With Unilateral Meniere's Disease

NCT02612337
View directory record Official record
Conditions
Meniere's Disease
Interventions
OTO-104, Placebo
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Jul 22, 2026, 4:00 PM EDT
Not listed Phase 2 Interventional

Lamotrigine and Bupropion for Meniere's Disease

NCT05420350
View directory record Official record
Conditions
Meniere Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural
Interventions
Lamotrigine and Bupropion, Placebo
Drug
Lead sponsor
Dent Neuroscience Research Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Amherst, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Jul 22, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

Study of Lamotrigine to Treat Ménière's Disease

NCT02158585
View directory record Official record
Conditions
Meniere's Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural
Interventions
Lamotrigine, Placebo
Drug
Lead sponsor
Dent Neuroscience Research Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Amherst, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Jul 22, 2026, 4:00 PM EDT
Active, not recruiting Phase 3 Interventional

SPI-1005 for the Treatment of Meniere's Disease (Open Label)

NCT06859788
View directory record Official record
Conditions
Meniere's Disease, Ménière's Disease
Interventions
Ebselen
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Boynton Beach, Florida • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 4:00 PM EDT
Completed Phase 2 Interventional

The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease

NCT01950312
View directory record Official record
Conditions
Autoimmune Inner Ear Disease
Interventions
gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Jul 22, 2026, 4:00 PM EDT
Terminated Phase 3 Interventional Results available

Study of OTO-104 in Subjects With Unilateral Meniere's Disease

NCT02717442
View directory record Official record
Conditions
Meniere's Disease
Interventions
OTO-104, Placebo
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Jul 22, 2026, 4:00 PM EDT
Active, not recruiting Phase 4 Interventional

Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease

NCT04815187
View directory record Official record
Conditions
Meniere Disease, Allergic Rhinitis, Vertigo
Interventions
Montelukast, Placebo
Drug
Lead sponsor
House Ear Institute
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jul 22, 2026, 4:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease

NCT01267994
View directory record Official record
Conditions
Sensorineural Hearing Loss, Autoimmune Inner Ear Disease
Interventions
Anakinra
Drug
Lead sponsor
Andrea Vambutas
Other
Eligibility
13 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Jul 22, 2026, 4:00 PM EDT
Recruiting Phase 2 Interventional

Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

NCT03587701
View directory record Official record
Conditions
Autoimmune Inner Ear Disease, Meniere's Disease
Interventions
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1), Placebo injection (Period 1), Anakinra 100Mg/0.67Ml Inj Syringe (Period 2), Placebo injection (Period 2)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 4:00 PM EDT
Completed Not applicable Interventional Results available

Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach

NCT02309099
View directory record Official record
Conditions
Unilateral Acoustic Neuroma, Meniere's Disease
Interventions
Cochlear Implant
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Jul 22, 2026, 4:00 PM EDT
Completed Phase 1 Interventional

OTO-104 for Meniere's Disease

NCT01084525
View directory record Official record
Conditions
Meniere's Disease
Interventions
OTO-104 (steroid) 3 mg, Placebo, OTO-104 (steroid) 12 mg
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Jul 22, 2026, 4:00 PM EDT
Recruiting Phase 4 Interventional

Treatment of Meniere's Disease With Migraine Medications

NCT05582837
View directory record Official record
Conditions
Ménière
Interventions
nortriptyline + topiramate
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
25 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

SPI-1005 for the Treatment of Patients With Meniere's Disease

NCT03325790
View directory record Official record
Conditions
Meniere's Disease
Interventions
200mg SPI-1005 BID, 400mg SPI-1005 BID, Placebo
Drug · Other
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
13
States / cities
Fresno, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Jul 22, 2026, 4:00 PM EDT
Active, not recruiting Not applicable Interventional

CI Following VS Removal or Labyrinthectomy

NCT03795675
View directory record Official record
Conditions
Vestibular Schwannoma, Meniere Disease
Interventions
Cochlear Implant
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 22, 2026, 4:00 PM EDT
Completed Not applicable Interventional

Evaluation of the OtoBand in Subjects With Self-reported Vertigo to Reduce Severity of Vertigo in a Real-world Setting

NCT04869020
View directory record Official record
Conditions
Vertigo
Interventions
Otoband, Sham A, Sham B
Device
Lead sponsor
Otolith Labs
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Jul 22, 2026, 4:00 PM EDT
Completed Phase 3 Interventional Results available

SPI-1005 for the Treatment of Meniere's Disease

NCT04677972
View directory record Official record
Conditions
Meniere Disease, Ménière
Interventions
Ebselen, Placebo
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • Roseville, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 22, 2026, 4:00 PM EDT
Terminated Phase 3 Interventional Results available

A 6-Month Extension Study of OTO-104 in Meniere's Disease

NCT02768662
View directory record Official record
Conditions
Meniere's Disease
Interventions
OTO-104
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Jul 22, 2026, 4:00 PM EDT
Completed Not applicable Interventional Results available

Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent

NCT02080312
View directory record Official record
Conditions
Meniere's Disease
Interventions
Magnevist (gadopentetate dimeglumine)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Jul 22, 2026, 4:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate SPI-1005 in Adults With Meniere's Disease

NCT02603081
View directory record Official record
Conditions
Meniere's Disease
Interventions
SPI-1005
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
19 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Los Angeles, California • New York, New York • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 4:00 PM EDT